Search International and National Patent Collections
|1. (WO2018146239) BIOMARKER FOR OUTCOME IN AML PATIENTS|
|Applicants:||INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE)
UNIVERSITÉ D'AIX MARSEILLE
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)
INSTITUT JEAN PAOLI & IRENE CALMETTES
|Title:||BIOMARKER FOR OUTCOME IN AML PATIENTS|
The present invention relates to a method for predicting the survival time of a patient suffering from acute myeloid leukemia (AML). The therapeutic management of patients, classified as intermediate in the ELN classification is difficult. By following studies on a cohort of 202 patients, the inventors show that NKp30 could be useful for reclassifying 40% patients with intermediate prognosis in the group of adverse prognosis. This biomarker can thus rendered the patients eligible to appropriate post remission therapy (i.e. chemotherapy and allograft). Thus, the present invention relates to a method for predicting the survival time of a patient suffering from acute myeloid leukemia (AML) and classified as intermediate in the cytogenetic classification and in the ELN classification comprising the step of determining in a sample (e.g. fresh total peripheral blood samples or peripheral blood mononuclear cells) the expression level of NKp30. Typically the level is determined by flow cytometry.